Clinical Research Directory

Inclusion Criteria: * Male or female, age reach and over 18 years at the time of signing informed consent, * Body mass index (BMI) between 18.0 and 35.0 kg/m\^2 (both inclusive), * Type 2 diabetes mellitus (as diagnosed clinically) before screening. * hemoglobin A1c of 7.5 - 9.0% (both inclusive) as assessed by central laboratory on the day of screening, * Treated with stable doses of oral antidiabetic drugs (OADs) , insulin or glucagon-like peptide-1 (GLP-1) receptor agonists (exenatide, liraglutide, etc.) within 3 months prior to screening; Exclusion Criteria: * Female who is pregnant, breast-feeding or intends to become pregnant or is of childbearing potential and not using a highly effective contraceptive method, * Anticipated initiation or change in concomitant medication (for more than 14 consecutive days) known to affect weight or glucose metabolism (e.g. treatment with orlistat, thyroid hormones, or systemic corticosteroids), * Any episodes (as declared by the participant or in the medical records) of diabetic ketoacidosis within 90 days before screening, * Presence or history of pancreatitis (acute or chronic) within 180 days before screening, * Any of the following: Myocardial infarction, stroke, hospitalization for unstable angina pectoris or transient ischaemic attack within 180 days before screening. Chronic heart failure classified as being in New York Heart Association Class IV at screening, * Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Verified by a fundus examination performed within the past 90 days before screening or in the period between screening and randomisation. Pharmacological pupil dilation is a requirement unless using a digital fundus photography camera specified for non dilated examination.